Imatinib can lead to long recurrence free survival in patients diagnosed with
gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality
of life for our patients. This study will use therapeutic drug monitoring to improve quality
of life and symptoms and assess how many patients maintain therapeutic levels. Free drug
levels and pharmokinetics of imatinib will also be monitored.